がん悪液質市場：治療法、機能、流通チャネル別-2025-2030年の世界予測

がん悪液質市場は、2023年に20億9,000万米ドルと評価され、2024年には22億4,000万米ドルに達すると予測され、CAGR 7.53％で成長し、2030年には34億8,000万米ドルに達すると予測されています。

がん悪液質は、重度の体重減少、筋肉の衰弱、食事摂取量の減少を特徴とする複雑な症候群であり、がん患者で頻繁に観察されます。この病態の定義は単なる食欲不振にとどまらず、重大な罹患率や死亡率のリスクにつながる代謝の変化を含んでいます。市場調査アナリストとして、この症候群を理解する必要性は、罹患患者のQOLと生存率を改善する効果的な治療オプションを開発することにあります。主な用途には、医薬品、栄養補助食品、支持療法などがあり、最終用途は病院、がん治療センター、在宅療養環境など多岐にわたる。市場成長の原動力となっているのは、がん罹患率の増加であり、より個別化された包括的な治療ソリューションが求められています。緩和ケアと患者中心の治療への注目の高まりが、市場の拡大をさらに後押ししています。

成長に影響を与える要因としては、バイオテクノロジーの進歩や代謝経路に関する研究の進行が挙げられ、革新的な医薬品開発の機会を提供しています。また、がんや悪液質に罹患しやすい老年人口の増加も、市場の可能性を高めています。しかし、複雑な医薬品開発プロセス、高コスト、厳しい規制要件などの課題が大きな障壁となっています。さらに、さまざまながん種や病期の影響を受けるがん悪液質の不均一性が、治療プロトコルの標準化を複雑にしています。

薬理学的介入と非薬理学的介入を組み合わせたマルチモーダルな治療アプローチを探求する機会が存在します。新たな研究分野としては、悪液質を引き起こす分子メカニズムの解明があり、これは標的治療につながる可能性があります。個別化医療とバイオマーカーを重視することで、個々の患者のニーズに応える革新的な製品が生まれる可能性があります。製薬会社、研究機関、医療提供者の連携は、こうした開発を促進する可能性があります。

市場の性質は非常にダイナミックであり、がん研究と治療技術の絶え間ない進歩がその原動力となっています。総合的な治療法の開発、患者の栄養状態の改善、患者管理システム全般の強化に注力する企業は、競争優位に立つことができます。高齢者腫瘍学のニッチ市場を特定し、悪液質管理に関する患者教育を強化することで、成長をさらに促すことができます。

市場力学：急速に進化するがん悪液質市場の主要市場インサイトを公開

がん悪液質市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 老年人口における悪液質の有病率の増加
  • 適切な償還政策の存在
  • ヘルスケアインフラの改善と治療に対する意識の高まりがん悪液質
• 市場抑制要因
  • 治療費の高騰
• 市場機会
  • がん悪液質治療のための技術の進歩
  • 治療薬発見のための研究開発活動の増加
• 市場の課題
  • 厳格な規制要件の実施とFDA認可の長期化

ポーターの5つの力：がん悪液質市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することで、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：がん悪液質市場における外部からの影響の把握

外部マクロ環境要因は、がん悪液質市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析がん悪液質市場における競合情勢の把握

がん悪液質市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスがん悪液質市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、がん悪液質市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨がん悪液質市場における成功への道筋を描く

がん悪液質市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 高齢者における悪液質の有病率の増加
    • 適切な償還ポリシーの存在
    • ヘルスケアインフラの改善と治療に対する意識の向上がん悪液質
  • 抑制要因
    • 治療費が高い
  • 機会
    • がん悪液質の治療のための技術的進歩
    • 治療薬の発見に向けた研究開発活動の増加
  • 課題
    • 厳格な規制要件の実施とFDAの長期にわたる承認
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 がん悪液質市場セラピー

• 併用療法
• コルチコステロイド
• プロゲストーゲン

第7章 がん悪液質市場機能別

• 食欲増進剤
• 減量安定剤

第8章 がん悪液質市場：流通チャネル別

• 病院売店
• オンライン薬局
• 小売薬局

第9章 南北アメリカのがん悪液質市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域のがん悪液質市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカのがん悪液質市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• AAVogen Inc.
• Actimed Therapeutics Ltd.
• Aeterna Zentaris Inc.
• Aphios Corporation
• Artelo Biosciences Inc.
• AVEO Pharmaceuticals Inc.
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Company
• Fresenius Kabi AG
• Green Cross Wellbeing Corporation
• Helsinn Healthcare SA
• INOVIO Pharmaceuticals Inc.
• Mankind Pharma Ltd.
• Merck & Co. Inc.
• MetaFines Co., Ltd.
• NeuBase Therapeutics, Inc.
• NGM Biopharmaceuticals Inc.
• Ono Pharmaceutical Co., Ltd.
• Pfizer Inc.
• Tetra Bio-Pharma

LIST OF FIGURES

• FIGURE 1. CANCER CACHEXIA MARKET RESEARCH PROCESS
• FIGURE 2. CANCER CACHEXIA MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL CANCER CACHEXIA MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL CANCER CACHEXIA MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES CANCER CACHEXIA MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES CANCER CACHEXIA MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. CANCER CACHEXIA MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. CANCER CACHEXIA MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. CANCER CACHEXIA MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL CANCER CACHEXIA MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL CANCER CACHEXIA MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. CANCER CACHEXIA MARKET DYNAMICS
• TABLE 7. GLOBAL CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL CANCER CACHEXIA MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL CANCER CACHEXIA MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL CANCER CACHEXIA MARKET SIZE, BY PROGESTOGENS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL CANCER CACHEXIA MARKET SIZE, BY APPETITE STIMULATORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL CANCER CACHEXIA MARKET SIZE, BY WEIGHT LOSS STABILIZERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL CANCER CACHEXIA MARKET SIZE, BY HOSPITAL STORES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL CANCER CACHEXIA MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL CANCER CACHEXIA MARKET SIZE, BY RETAIL PHARMACY STORES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. AMERICAS CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 22. ARGENTINA CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 23. ARGENTINA CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 25. BRAZIL CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 26. BRAZIL CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 27. BRAZIL CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 28. CANADA CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 29. CANADA CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 30. CANADA CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 31. MEXICO CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 32. MEXICO CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 34. UNITED STATES CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 35. UNITED STATES CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES CANCER CACHEXIA MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 38. ASIA-PACIFIC CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 39. ASIA-PACIFIC CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 42. AUSTRALIA CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 43. AUSTRALIA CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 44. AUSTRALIA CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 45. CHINA CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 46. CHINA CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 47. CHINA CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 48. INDIA CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 49. INDIA CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 50. INDIA CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 51. INDONESIA CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 52. INDONESIA CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 53. INDONESIA CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 54. JAPAN CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 55. JAPAN CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 56. JAPAN CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 57. MALAYSIA CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 58. MALAYSIA CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 59. MALAYSIA CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 60. PHILIPPINES CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 61. PHILIPPINES CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 62. PHILIPPINES CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 63. SINGAPORE CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 64. SINGAPORE CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 65. SINGAPORE CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 66. SOUTH KOREA CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 67. SOUTH KOREA CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 68. SOUTH KOREA CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 69. TAIWAN CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 70. TAIWAN CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 71. TAIWAN CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 72. THAILAND CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 73. THAILAND CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 74. THAILAND CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 75. VIETNAM CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 76. VIETNAM CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 77. VIETNAM CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 78. EUROPE, MIDDLE EAST & AFRICA CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 79. EUROPE, MIDDLE EAST & AFRICA CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 82. DENMARK CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 83. DENMARK CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 84. DENMARK CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 85. EGYPT CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 86. EGYPT CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 87. EGYPT CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 88. FINLAND CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 89. FINLAND CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 90. FINLAND CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 91. FRANCE CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 92. FRANCE CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 93. FRANCE CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 94. GERMANY CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 95. GERMANY CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 96. GERMANY CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 97. ISRAEL CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 98. ISRAEL CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 99. ISRAEL CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 100. ITALY CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 101. ITALY CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 102. ITALY CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 103. NETHERLANDS CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 104. NETHERLANDS CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 105. NETHERLANDS CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 106. NIGERIA CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 107. NIGERIA CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 108. NIGERIA CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 109. NORWAY CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 110. NORWAY CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 111. NORWAY CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 112. POLAND CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 113. POLAND CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 114. POLAND CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 115. QATAR CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 116. QATAR CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 117. QATAR CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 118. RUSSIA CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 119. RUSSIA CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 120. RUSSIA CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 121. SAUDI ARABIA CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 122. SAUDI ARABIA CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 123. SAUDI ARABIA CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 124. SOUTH AFRICA CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 125. SOUTH AFRICA CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH AFRICA CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 127. SPAIN CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 128. SPAIN CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 129. SPAIN CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 130. SWEDEN CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 131. SWEDEN CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 132. SWEDEN CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 133. SWITZERLAND CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 134. SWITZERLAND CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 135. SWITZERLAND CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 136. TURKEY CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 137. TURKEY CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 138. TURKEY CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 139. UNITED ARAB EMIRATES CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 140. UNITED ARAB EMIRATES CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 141. UNITED ARAB EMIRATES CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 142. UNITED KINGDOM CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 143. UNITED KINGDOM CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
• TABLE 144. UNITED KINGDOM CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 145. CANCER CACHEXIA MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 146. CANCER CACHEXIA MARKET, FPNV POSITIONING MATRIX, 2023

The Cancer Cachexia Market was valued at USD 2.09 billion in 2023, expected to reach USD 2.24 billion in 2024, and is projected to grow at a CAGR of 7.53%, to USD 3.48 billion by 2030.

Cancer cachexia is a complex syndrome characterized by severe weight loss, muscle wasting, and reduced food intake, frequently observed in cancer patients. The condition's definition extends beyond mere anorexia, encompassing metabolic changes that lead to significant morbidity and mortality risks. As a market research analyst, the necessity for understanding this syndrome lies in developing effective treatment options to improve the quality of life and survival rates of affected patients. Key applications include pharmaceuticals, nutritional supplements, and supportive care therapies, with end-use spanning hospitals, cancer treatment centers, and home care settings. Market growth is driven by increasing cancer prevalence, demanding more personalized and comprehensive therapeutic solutions. The growing focus on palliative care and patient-centric treatment further propels the market's expansion.

Factors impacting growth include advancements in biotechnology and ongoing research into metabolic pathways, providing opportunities for innovative drug development. The growing geriatric population, susceptible to cancer and, hence, cachexia, also boosts market potential. However, challenges such as complex drug development processes, high costs, and stringent regulatory requirements pose significant barriers. Furthermore, the heterogeneity of cancer cachexia, influenced by various cancer types and stages, complicates the standardization of treatment protocols.

Opportunities exist in exploring multi-modal treatment approaches, combining pharmacological and non-pharmacological interventions. Emerging research areas include understanding molecular mechanisms driving cachexia, which could lead to targeted therapies. Emphasis on personalized medicine and biomarkers offers potential for innovative products that cater to individual patient needs. Collaborations between pharmaceutical companies, research institutions, and healthcare providers can expedite these developments.

The market's nature is highly dynamic, driven by continual advancements in cancer research and therapeutic technologies. Companies focusing on developing integrated treatment regimes, improving patient nutrition, and enhancing overall patient management systems stand to gain a competitive edge. Identifying niche markets within geriatric oncology and enhancing patient education about cachexia management can further stimulate growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cancer Cachexia Market

The Cancer Cachexia Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of cachexia amongst the geriatric population
  • Presence of adequate reimbursement policies
  • Improving healthcare infrastructure and rise in awareness to treat cancer cachexia
• Market Restraints
  • High cost of treatment
• Market Opportunities
  • Technological advancements for the treatment of cancer cachexia
  • Rising number of research and development activities for the discovery of therapeutic drugs
• Market Challenges
  • Implementation of stringent regulatory requirements and lengthy FDA approval

Porter's Five Forces: A Strategic Tool for Navigating the Cancer Cachexia Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cancer Cachexia Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cancer Cachexia Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cancer Cachexia Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cancer Cachexia Market

A detailed market share analysis in the Cancer Cachexia Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cancer Cachexia Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cancer Cachexia Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cancer Cachexia Market

A strategic analysis of the Cancer Cachexia Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cancer Cachexia Market, highlighting leading vendors and their innovative profiles. These include AAVogen Inc., Actimed Therapeutics Ltd., Aeterna Zentaris Inc., Aphios Corporation, Artelo Biosciences Inc., AVEO Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Fresenius Kabi AG, Green Cross Wellbeing Corporation, Helsinn Healthcare SA, INOVIO Pharmaceuticals Inc., Mankind Pharma Ltd., Merck & Co. Inc., MetaFines Co., Ltd., NeuBase Therapeutics, Inc., NGM Biopharmaceuticals Inc., Ono Pharmaceutical Co., Ltd., Pfizer Inc., and Tetra Bio-Pharma.

Market Segmentation & Coverage

This research report categorizes the Cancer Cachexia Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Therapy, market is studied across Combination Therapies, Corticosteroids, and Progestogens.
• Based on Functionality, market is studied across Appetite Stimulators and Weight Loss Stabilizers.
• Based on Distribution Channel, market is studied across Hospital Stores, Online Pharmacy, and Retail Pharmacy Stores.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of cachexia amongst the geriatric population
    • 5.1.1.2. Presence of adequate reimbursement policies
    • 5.1.1.3. Improving healthcare infrastructure and rise in awareness to treat cancer cachexia
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of treatment
  • 5.1.3. Opportunities
    • 5.1.3.1. Technological advancements for the treatment of cancer cachexia
    • 5.1.3.2. Rising number of research and development activities for the discovery of therapeutic drugs
  • 5.1.4. Challenges
    • 5.1.4.1. Implementation of stringent regulatory requirements and lengthy FDA approval
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Cancer Cachexia Market, by Therapy

• 6.1. Introduction
• 6.2. Combination Therapies
• 6.3. Corticosteroids
• 6.4. Progestogens

7. Cancer Cachexia Market, by Functionality

• 7.1. Introduction
• 7.2. Appetite Stimulators
• 7.3. Weight Loss Stabilizers

8. Cancer Cachexia Market, by Distribution Channel

• 8.1. Introduction
• 8.2. Hospital Stores
• 8.3. Online Pharmacy
• 8.4. Retail Pharmacy Stores

9. Americas Cancer Cachexia Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Cancer Cachexia Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Cancer Cachexia Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AAVogen Inc.
• 2. Actimed Therapeutics Ltd.
• 3. Aeterna Zentaris Inc.
• 4. Aphios Corporation
• 5. Artelo Biosciences Inc.
• 6. AVEO Pharmaceuticals Inc.
• 7. Boehringer Ingelheim International GmbH
• 8. Bristol-Myers Squibb Company
• 9. Fresenius Kabi AG
• 10. Green Cross Wellbeing Corporation
• 11. Helsinn Healthcare SA
• 12. INOVIO Pharmaceuticals Inc.
• 13. Mankind Pharma Ltd.
• 14. Merck & Co. Inc.
• 15. MetaFines Co., Ltd.
• 16. NeuBase Therapeutics, Inc.
• 17. NGM Biopharmaceuticals Inc.
• 18. Ono Pharmaceutical Co., Ltd.
• 19. Pfizer Inc.
• 20. Tetra Bio-Pharma